These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 18163453)

  • 1. For better or worse: The effect of levodopa on speech in Parkinson's disease.
    Ho AK; Bradshaw JL; Iansek R
    Mov Disord; 2008 Mar; 23(4):574-80. PubMed ID: 18163453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-induced alterations in speech rate in advanced Parkinson's disease.
    De Letter M; Santens P; De Bodt M; Boon P; Van Borsel J
    Acta Neurol Belg; 2006 Mar; 106(1):19-22. PubMed ID: 16776432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of levodopa on word intelligibility in Parkinson's disease.
    De Letter M; Santens P; Van Borsel J
    J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease.
    Goberman AM
    Med Sci Monit; 2005 Mar; 11(3):CR109-16. PubMed ID: 15735562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Speech and voice disorders in Parkinson's disease].
    Martnez-Sánchez F
    Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glottographic measures before and after levodopa treatment in Parkinson's disease.
    Jiang J; Lin E; Wang J; Hanson DG
    Laryngoscope; 1999 Aug; 109(8):1287-94. PubMed ID: 10443835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.
    De Letter M; Santens P; Estercam I; Van Maele G; De Bodt M; Boon P; Van Borsel J
    Clin Linguist Phon; 2007 Oct; 21(10):783-91. PubMed ID: 17882694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor instability in parkinsonian speech intensity.
    Ho AK; Iansek R; Bradshaw JL
    Neuropsychiatry Neuropsychol Behav Neurol; 2001; 14(2):109-16. PubMed ID: 11417664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease.
    De Letter M; Van Borsel J; Boon P; De Bodt M; Dhooge I; Santens P
    Int J Speech Lang Pathol; 2010 Oct; 12(5):405-13. PubMed ID: 20602581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
    Herzog J; Möller B; Witt K; Pinsker MO; Deuschl G; Volkmann J
    Mov Disord; 2009 Jun; 24(8):1206-10. PubMed ID: 19412937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems.
    Plowman-Prine EK; Okun MS; Sapienza CM; Shrivastav R; Fernandez HH; Foote KD; Ellis C; Rodriguez AD; Burkhead LM; Rosenbek JC
    NeuroRehabilitation; 2009; 24(2):131-44. PubMed ID: 19339752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson's disease.
    Rusz J; Cmejla R; Ruzickova H; Ruzicka E
    J Acoust Soc Am; 2011 Jan; 129(1):350-67. PubMed ID: 21303016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease.
    De Letter M; Santens P; De Bodt M; Van Maele G; Van Borsel J; Boon P
    Clin Neurol Neurosurg; 2007 Jul; 109(6):495-500. PubMed ID: 17509751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pain intensity on and off levodopa in patients with Parkinson's disease.
    Nebe A; Ebersbach G
    Mov Disord; 2009 Jun; 24(8):1233-7. PubMed ID: 19412949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Speech dysfunction in early Parkinson's disease.
    Stewart C; Winfield L; Hunt A; Bressman SB; Fahn S; Blitzer A; Brin MF
    Mov Disord; 1995 Sep; 10(5):562-5. PubMed ID: 8552106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of gait and speech in Parkinson's disease: hypokinetic or dysrhythmic disorders?
    Cantiniaux S; Vaugoyeau M; Robert D; Horrelou-Pitek C; Mancini J; Witjas T; Azulay JP
    J Neurol Neurosurg Psychiatry; 2010 Feb; 81(2):177-84. PubMed ID: 19793764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of dysprosody in Parkinson's disease over time--a longitudinal study.
    Skodda S; Rinsche H; Schlegel U
    Mov Disord; 2009 Apr; 24(5):716-22. PubMed ID: 19117364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
    Pawlukowska W; Gołąb-Janowska M; Safranow K; Rotter I; Amernik K; Honczarenko K; Nowacki P
    Neurol Neurochir Pol; 2015; 49(5):302-6. PubMed ID: 26377981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of speech therapy and pharmacological treatment in prosody of parkinsonians.
    Azevedo LL; Souza IS; Oliveira PM; Cardoso F
    Arq Neuropsiquiatr; 2015 Jan; 73(1):30-5. PubMed ID: 25608124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa.
    Pal PK; Sathyaprabha TN; Tuhina P; Thennarasu K
    Mov Disord; 2007 Feb; 22(3):420-4. PubMed ID: 17230476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.